awmsg logo



docetaxel (Taxotere®)


Reference No. 112

Publication date:
18/07/2008


Appraisal information

docetaxel (Taxotere®) concentrate for solution for infusion


Company: Sanofi-Aventis Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 14/05/2008
AWMSG meeting date: 13/06/2008
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1008
Ministerial ratification: 17/07/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Docetaxel (Taxotere®) is recommended for restricted use within NHS Wales in combination with cisplatin and 5-fluorouracil (5-FU) for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Docetaxel (Taxotere®) should be restricted for use as an induction treatment for patients of good performance status (0 or 1) anticipated to be receiving chemo-radiotherapy. Docetaxel (Taxotere®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download